Massachusetts Society of Clinical Oncologists - FDA Approves romiplostim (NPlate) for pediatric patients with ITP

"The voice for cancer physicians and their patients in Massachusetts."

Home
For Professionals
FDA Approvals
FDA Approves romiplostim (NPlate) for pediatric patients with ITP

FDA Approves romiplostim (NPlate) for pediatric patients with ITP

14 Jan 2019 3:08 PM | Anonymous

The U.S. Food and Drug Administration approved romiplostim (Nplate; Amgen) for pediatric patients 1 year of age and older with immune thrombocytopenia (ITP) for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. Read full press release.

Massachusetts Society of Clinical Oncologists

P.O. Box 549154, Waltham, MA, 02454
Tel: 781.434.7329 | Fax: 781.464.4896 | email: msco@mms.org